Atrium Therapeutics, Inc. (NASDAQ:RNA)
| Market Cap | $149.27M-53.1% |
| Revenue (ttm) | $38.82M |
| Net Income | -$89.15M |
| EPS | -$4.10 |
| Shares Out | 21.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 319,586 |
| Open | $7.01 |
| Previous Close | $6.98 |
| Day's Range | $6.88 - $7.44 |
| 52-Week Range | $6.36 - $16.77 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | $20.00(+189.02%) |
| Earnings Date | Feb 11, 2027 |
About RNA
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Analyst consensus
1 firm rating RNA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 11, 2027Earnings report
$RNA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RNA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RNA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RNA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RNA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RNA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RNA
| VTIVanguard Morningstar Total Stock Market ETF | $3.38M |
| IWMiShares Russell 2000 ETF | $2.66M |
| VXFVanguard Extended Market ETF | $1.56M |
| VTWOVanguard Russell 2000 ETF | $734.22K |
| IWOiShares Russell 2000 Growth ETF | $697.16K |
| SCHASchwab U.S. Small-Cap ETF | $587.44K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from RNA’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| MOON | Direxion Moonshot Innovators ETF | 2.33% |
| MNTL | Tema Neuroscience And Mental Health ETF | 1.88% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.14% |
| RUSC | Russell Investments Exchange Traded Funds - Russell Investments US Small Cap Equity ETF | 0.07% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.03% |
| AVIE | Avantis Inflation Focused Equity ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
